Target type: biologicalprocess
Any process that modulates the frequency, rate, or extent of myeloid cell apoptotic process. [GOC:add, GOC:mtg_apoptosis]
The regulation of myeloid cell apoptotic process is a complex and tightly controlled process that plays a crucial role in maintaining homeostasis within the immune system. Myeloid cells, a diverse population of immune cells including monocytes, macrophages, neutrophils, and dendritic cells, are essential for both innate and adaptive immunity. Apoptosis, or programmed cell death, is a physiological process that eliminates damaged or unwanted cells without triggering an inflammatory response.
The regulation of myeloid cell apoptosis is influenced by a multitude of factors, including:
1. **Extrinsic pathways:** These pathways are triggered by external stimuli, such as death receptors expressed on the cell surface. Binding of specific ligands, such as TNF-α, TRAIL, or FasL, to these receptors activates a cascade of intracellular signaling events leading to caspase activation and apoptosis.
2. **Intrinsic pathways:** This pathway is activated by intracellular stress signals, including DNA damage, oxidative stress, and growth factor deprivation. These stressors activate pro-apoptotic proteins like Bax and Bak, leading to mitochondrial outer membrane permeabilization and release of cytochrome c. Cytochrome c then activates caspase-9, initiating the caspase cascade.
3. **Survival signals:** Myeloid cells are also equipped with survival pathways that counteract apoptotic signals. These pathways are often activated by growth factors, cytokines, and other signaling molecules. Activation of survival pathways promotes the expression of anti-apoptotic proteins, such as Bcl-2 and Bcl-XL, which inhibit the intrinsic apoptotic pathway.
4. **Microenvironment:** The surrounding microenvironment plays a significant role in regulating myeloid cell apoptosis. Factors such as oxygen tension, pH, and the presence of inflammatory mediators can influence apoptotic pathways.
Regulation of myeloid cell apoptosis is critical for various physiological processes:
1. **Immune homeostasis:** Maintaining the appropriate number of myeloid cells is crucial for a balanced immune response. Excess myeloid cells can contribute to chronic inflammation and autoimmune disorders, while insufficient numbers can compromise immune defenses.
2. **Inflammatory resolution:** Apoptosis of activated myeloid cells is essential for resolving inflammation and preventing tissue damage.
3. **Tumor suppression:** Myeloid cells can contribute to tumor growth by suppressing anti-tumor immunity. Induction of apoptosis in tumor-associated myeloid cells can enhance anti-tumor immune responses.
4. **Pathogen clearance:** Myeloid cell apoptosis can be exploited by pathogens to evade the immune system. Some pathogens can induce apoptosis in immune cells, hindering their ability to eliminate the infection.
Disruptions in the regulation of myeloid cell apoptosis can lead to various pathologies, including:
1. **Autoimmune diseases:** Dysregulated apoptosis can contribute to the development of autoimmune diseases, where immune cells inappropriately target and attack self-tissues.
2. **Inflammatory diseases:** Defects in apoptotic pathways can lead to chronic inflammation, contributing to the development of inflammatory bowel disease, rheumatoid arthritis, and other inflammatory conditions.
3. **Cancer:** Both excessive and insufficient apoptosis can contribute to cancer development. Reduced apoptosis can allow for tumor cell survival and proliferation, while excessive apoptosis can contribute to immune suppression and tumor growth.
The intricate regulation of myeloid cell apoptotic process is essential for maintaining immune homeostasis and orchestrating appropriate responses to various stimuli. Understanding the mechanisms of myeloid cell apoptosis is crucial for developing effective therapies for a wide range of human diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Thyroid hormone receptor alpha | A thyroid hormone receptor alpha that is encoded in the genome of human. [PRO:HJD, UniProtKB:P10827] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
amiodarone | amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias. Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance. | 1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound | cardiovascular drug |
3,3',5-triiodothyroacetic acid | tiratricol : A monocarboxylic acid that is (4-hydroxy-3,5-diiodophenyl)acetic acid in which the phenolic hydroxy group has been replaced by a 4-hydroxy-3-iodophenoxy group. It is a thyroid hormone analogue that has been used in the treatment of thyroid hormone resistance syndrome. | ||
3,3',5-triiodothyropropionic acid | aromatic ether | ||
thyroxine | thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions. Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism. | 2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine; thyroxine zwitterion | antithyroid drug; human metabolite; mouse metabolite; thyroid hormone |
triiodothyronine | 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism. Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. | 2-halophenol; amino acid zwitterion; iodophenol; iodothyronine | human metabolite; mouse metabolite; thyroid hormone |
mifepristone | Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME. | 3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound | abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive |
tetraiodothyroacetic acid | 3,3',5,5'-tetraiodothyroacetic acid : A monocarboxylic acid that is thyroacetic acid carrying four iodo substituents at positions 3, 3', 5 and 5'. tetraiodothyroacetic acid: RN given refers to parent cpd; structure | 2-halophenol; aromatic ether; iodophenol; monocarboxylic acid | apoptosis inducer; human metabolite; thyroid hormone |
3,5-dimethyl-3'-isopropyl-l-thyronine | 3,5-dimethyl-3'-isopropyl-L-thyronine: RN given refers to (L)-isomer | ||
pregna-4,17-diene-3,16-dione | pregna-4,17-diene-3,16-dione: steroid from guggulu extract; RN & N1 from C1 Form index; RN given refers to cpd without isomeric designation; structure in first source; antagonist of farnesoid X receptor | 3-hydroxy steroid | androgen |
gc 1 compound | GC 1 compound: structure in first source | diarylmethane | |
kb 141 | KB 141: an anticholesteremic agent; structure in first source | ||
kb 130015 | KB 130015: structure in first source | ||
cgs 23425 | CGS 23425: structure given in first source | ||
3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid | 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid: a thyroid receptor beta1 agonist; structure in first source | ||
kb 2115 | 3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid: a thyroid hormone receptor agonist with anticholesteremic activity | ||
fg-4592 | roxadustat : An N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid. It is an inhibitor of hypoxia inducible factor prolyl hydroxylase (HIF-PH). roxadustat: structure in first source | aromatic ether; isoquinolines; N-acylglycine | EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor |
mgl-3196 | resmetirom: a thyroid hormone receptor-beta agonist |